JPMorgan assumed coverage of InnovAge (INNV) with an Underweight rating and $5 price target The firm views current outpatient environment to be most favorable for companies with lower reimbursement exposure to federal funding. The analyst believes InnovAge is facing challenges balancing growth while navigating the regulatory backdrop.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INNV: